Animal models

Rats

Dosage form

2 mg/kg, i.v.

Application

Two effects of pancuronium bromide on heart rate in vivo: A short-lasting injection effect, which may be due to an indirect sympathomimetic action, and a longer-lasting potentiation of cardiac sympathetic responses which is at least partly due to blockade of neuronal noradrenaline uptake.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Pancuronium Dibromide is a bis-quaternary steroid that is a competitive nicotinic antagonist.Target: nAChRPancuronium Dibromide is a competitive AChR antagonist (IC50 = 5.5 nM) and acts as a skeletal muscle relaxant. Pancuronium Dibromide interrupts neuromuscular transmission by competing with acetylcholine for receptor sites on the motor end-plate. Pancuronium dibromide is a non-depolarizing agent. Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is (unlike suxamethonium) a non-depolarizing agent, which means that it causes no spontaneous depolarizations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration [1-3].

References:
[1]. Fryer, A.D. and J. Maclagan, Pancuronium and gallamine are antagonists for pre- and post-junctional muscarinic receptors in the guinea-pig lung. Naunyn Schmiedebergs Arch Pharmacol, 1987. 335(4): p. 367-71.
[2]. Maestrone, E., et al., Extracellular pancuronium affects sodium current in chick embryo sensory neurones. Br J Pharmacol, 1994. 111(1): p. 283-7.
[3]. Lowenick, C.V., et al., Open channel and competitive block of nicotinic receptors by pancuronium and atracurium. Eur J Pharmacol, 2001. 413(1): p. 31-5.